NCT01390805
Completed
Not Applicable
Special Drug Use Investigation for VALTREX (Valaciclovir) (Suppression Prophylaxis)
Overview
- Phase
- Not Applicable
- Intervention
- Valaciclovir Hydrochloride.
- Conditions
- Genital Herpes
- Sponsor
- GlaxoSmithKline
- Enrollment
- 462
- Primary Endpoint
- The number of adverse events in Japanese subjects with recurrent genital herpes treated with valaciclovir
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
The purpose of this study is to collect and assess information on proper use of valaciclovir regarding safety and efficacy of long-term use in suppressive therapy for subjects with recurrent genital herpes.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subjects who started suppressive therapy for recurrent genital herpes for the first time
Exclusion Criteria
- •Subjects with a history of hypersensitivity to the ingredients of VALTREX or aciclovir
Arms & Interventions
Subjects with recurrent genital herpes
Intervention: Valaciclovir Hydrochloride.
Outcomes
Primary Outcomes
The number of adverse events in Japanese subjects with recurrent genital herpes treated with valaciclovir
Time Frame: 1 year
Similar Trials
Completed
Not Applicable
Special Drug Use Investigation for VALTREX (Valaciclovir) (Pediatrics Chickenpox)VaricellaNCT01390857GlaxoSmithKline379
Unknown
Phase 3
A Study of Valacyclovir as Treatment for Genital Herpes Simplex Virus in HIV-Infected PatientsHerpes SimplexHIV InfectionsHerpes GenitalisNCT00005663Glaxo Wellcome
Completed
Not Applicable
Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)Venous ThromboembolismNCT02558465Bayer2,540
Active, not recruiting
Phase 2
Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired InfantsCmv CongenitalCMVCongenital CmvSNHLSensorineural Hearing LossNCT03107871Albert Park52
Completed
Phase 3
Evaluation Of Valaciclovir In Patients With ChickenpoxVaricellaNCT00169416GlaxoSmithKline43